Hereditary Angioedema Therapeutic Market Growing at 16.79% CAGR Through 2034

Hereditary Angioedema Therapeutic Market Overview

The Hereditary Angioedema Therapeutic Market was valued at US$ 7.61 Bn in 2025 and is projected to reach US$ 30.76 Bn by 2034, expanding at a CAGR of 16.79% during 2026–2034. The industry covers preventive and on-demand medicines, including C1-esterase inhibitors, bradykinin B2 receptor antagonists, kallikrein inhibitors, and other therapies. MMR recorded approximately 422,700 prevalent cases worldwide in 2025 and noted that under-reporting and misdiagnosis may conceal additional patients.

Request Sample Report at: https://www.maximizemarketresearch.com/request-sample/37140/

The Hereditary Angioedema Therapeutic market is becoming more important as developers move beyond conventional intravenous treatment toward subcutaneous, oral, RNA-targeted, monoclonal-antibody, and gene-editing approaches. Awareness, launches, reimbursement, and distribution agreements are widening access, while misdiagnosis can still delay appropriate therapy.

Key Growth Drivers Fueling the Hereditary Angioedema Therapeutic Market

Increasing diagnosed cases: MMR identifies the growing number of HAE cases as the main market driver. Better recognition can bring undiagnosed patients into specialist care.

Persistent misdiagnosis: HAE symptoms may be mistaken for allergies or other conditions. Education, advocacy, and genetic assessment can improve treatment uptake.

Novel treatment mechanisms: Development now spans C1 replacement, kallikrein inhibition, bradykinin receptor blockade, Factor XIIa inhibition, RNA-targeted medicine, and in vivo gene editing. They aim to reduce attacks, simplify administration, or deliver faster relief.

Reimbursement and healthcare infrastructure: MMR attributes North America’s leadership partly to better reimbursement and developed healthcare systems. Specialist access supports adoption.

More convenient administration: Oral, subcutaneous, autoinjector, and less-frequent dosing options can lower the burden of repeated infusions. Competition centers on relief, prevention, convenience, and quality of life.

Market Segmentation — By Drug Class, Treatment Type & Route

By drug class, the Hereditary Angioedema Therapeutic Market includes C1-esterase inhibitors, bradykinin B2 receptor antagonists, kallikrein inhibitors, and other therapies. MMR identifies C1-esterase inhibitors as the segment expected to hold the highest market share, but the public summary does not provide a numerical share or exact segment CAGR.

By treatment type, the market is divided into prophylaxis and on-demand therapy. Prophylaxis reduces attacks, while on-demand medicines are used after symptoms begin. MMR does not disclose a dominant treatment type or percentage shares.

By route of administration, the market covers intravenous, subcutaneous, and oral therapies. This reflects a shift from infusions toward self-administered injections and oral products. No route-level shares are publicly disclosed.

C1-esterase inhibitors remain the documented leader because they address deficient or dysfunctional C1 inhibitor. Kallikrein, bradykinin, RNA, Factor XIIa, and gene-editing therapies are nevertheless increasing competitive intensity.

Regional Analysis  Where Is the Hereditary Angioedema Therapeutic Market Growing Fastest?

United States

The United States is included in North America, which held the highest revenue share in 2025. MMR links regional leadership to new launches, better reimbursement, developed healthcare infrastructure, and rising awareness, but publishes no separate U.S. value.

United Kingdom

The United Kingdom is covered within Europe by drug class, treatment type, and route. MMR provides no UK-specific market size, share, or growth rate.

Germany

Germany is also included in the European scope. The public summary does not disclose German revenue, CAGR, or a dominant national segment.

Japan

Japan forms part of the Asia-Pacific assessment. Country-level market values and growth rankings are not disclosed.

South Korea

South Korea is included within Asia-Pacific. MMR publishes no separate South Korean size, share, or CAGR.

China

China is assessed as part of Asia-Pacific. The public report description does not provide a China-specific numerical forecast.

India

India is included in Asia-Pacific country coverage. No India-specific market value, share, or growth rate is publicly stated.

North America is the dominant region in the Hereditary Angioedema Therapeutic Market. MMR does not identify the fastest-growing region, so no unsupported ranking is assigned. Based on its reimbursement, infrastructure, awareness, and launch activity, North America is the strongest evidenced commercial investment hotspot.

Competitive Landscape  Leading Companies in the Hereditary Angioedema Therapeutic Market

BioCryst Pharmaceuticals, Inc.: BioCryst is the first company listed in MMR’s competitive landscape. MMR identifies distribution agreements as a route to broader geographic reach.

Ionis Pharmaceuticals, Inc.: Ionis is an MMR-listed developer and secured U.S. approval for DAWNZERA in August 2025. The approval expanded competition in long-term prophylaxis.

Pharming Group N.V.: Pharming is listed among the key participants and contributes to competition among established rare-disease therapy companies.

CSL Limited: CSL is a key listed company, and MMR records the April 2025 commercial rollout of ANDEMBRY as a targeted Factor XIIa inhibitor for long-term prophylaxis.

Shire Plc: MMR lists Shire Plc as its fifth key company. The public summary provides no separate 2025–2026 strategic development or company-level share for this entry.

Request Sample Report at: https://www.maximizemarketresearch.com/request-sample/37140/

Recent Developments & Strategic Moves

• On June 16, 2025, the U.S. FDA approved CSL’s ANDEMBRY, a once-monthly prophylactic treatment targeting Factor XIIa for patients aged 12 years and older.
• On July 7, 2025, the FDA approved KalVista Pharmaceuticals’ EKTERLY, the first oral on-demand treatment for acute HAE attacks in patients aged 12 years and older.
• On August 21, 2025, the FDA approved Ionis Pharmaceuticals’ DAWNZERA, an RNA-targeted prophylactic medicine administered every four or eight weeks.
• On April 27, 2026, Intellia Therapeutics reported positive Phase III HAELO results for lonvoguran ziclumeran and began a rolling U.S. biologics license application for the one-time in vivo gene-editing candidate.
• On July 6, 2026, the FDA accepted Pharvaris’ application for deucrictibant immediate-release as an oral on-demand therapy, with an action date of April 23, 2027.

AI & Digital Transformation Impact on Hereditary Angioedema Therapeutic Market

How is AI changing the Hereditary Angioedema Therapeutic Market? MMR does not identify a specific commercial AI program, but its emphasis on under-reporting and misdiagnosis indicates where digital tools may help. AI-assisted review of histories, recurrent swelling patterns, laboratory findings, and genetic information could flag patients requiring specialist assessment, while digital attack diaries may improve monitoring. This is a forward-looking inference rather than an MMR market statistic.

Automation may also support trial recruitment, pharmacovigilance, manufacturing quality control, patient assistance, and rare-disease supply planning. They do not replace clinical diagnosis or physician oversight.

Future Outlook  Investment Opportunities & Emerging Trends

The future of the Hereditary Angioedema Therapeutic Market is moving toward earlier diagnosis, oral rescue therapy, longer-acting prophylaxis, RNA-targeted medicine, Factor XIIa inhibition, and potentially one-time gene editing. Investment is likely to focus on treatments that reduce attacks, improve adherence, expand pediatric access, and reach underdiagnosed patients. North America remains the established commercial base, while distribution agreements can support expansion across Europe and Asia-Pacific. Competition will increasingly be defined by speed, durability, convenience, and the potential for treatment-free intervals.

Related Reports

Retinitis Pigmentosa Market https://www.maximizemarketresearch.com/market-report/retinitis-pigmentosa-market/187773/

Global Sterile Injectable Drugs Market https://www.maximizemarketresearch.com/market-report/global-sterile-injectable-drugs-market/75542/

Global Health Care Interoperability Solutions Market https://www.maximizemarketresearch.com/market-report/global-health-care-interoperability-solutions-market/85014/

Expert Commentary

According to Komal Patil, Research Manager at Maximize Market Research, “The Hereditary Angioedema Therapeutic Market is projected to rise from US$ 7.61 Bn in 2025 to US$ 30.76 Bn by 2034 at a CAGR of 16.79%, supported by greater diagnosis, stronger reimbursement, and rapid therapeutic innovation. Investment is moving toward oral on-demand medicines, extended prophylaxis, RNA-targeted platforms, and gene-editing candidates that could reduce the lifelong treatment burden.”

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

Contact Us

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com